Pulmonary hypertension with left- sided heart disease

被引:102
作者
Guazzi, Marco [1 ]
Arena, Ross [2 ]
机构
[1] Univ Milan, Cardiopulm Unit, San Paolo Hosp, I-20142 Milan, Italy
[2] Virginia Commonwealth Univ, Dept Phys Therapy, Richmond, VA 23284 USA
关键词
VENTRICULAR EJECTION FRACTION; INHALED NITRIC-OXIDE; SHORT-TERM PROGNOSIS; VASCULAR-RESISTANCE; VENTILATORY EFFICIENCY; ARTERY PRESSURE; DOUBLE-BLIND; TRANSPLANT CANDIDATES; ENDOTHELIN ANTAGONIST; EXERCISE INTOLERANCE;
D O I
10.1038/nrcardio.2010.144
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) with left-sided heart disease is defined, according to the latest Venice classification, as a Group 2 PH, which includes left-sided ventricular or atrial disease, and left-sided valvular diseases. These conditions are all associated with increased left ventricular filling pressure. Although PH with left-sided heart disease is a common entity, and long-term follow-up trials have provided firm recognition that development of left-sided PH carries a poor outcome, available data on incidence, pathophysiology, and therapy are sparse. Mitral stenosis was reported as the most frequent cause of PH several decades ago, but PH with left-sided heart disease is now usually caused by systemic hypertension and ischemic heart disease. In patients with these conditions, PH develops as a consequence of impaired left ventricular relaxation and distensibility. Chronic sustained elevation of cardiogenic blood pressure in pulmonary capillaries leads to a cascade of untoward retrograde anatomical and functional effects that represent specific targets for therapeutic intervention. The pathophysiological and clinical importance of the hemodynamic consequences of left-sided heart disease, starting with lung capillary injury and leading to right ventricular overload and failure, are discussed in this Review, focusing on PH as an evolving contributor to heart failure that may be amenable to novel interventions.
引用
收藏
页码:648 / 659
页数:12
相关论文
共 129 条
[1]   PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY [J].
ABRAMSON, SV ;
BURKE, JF ;
KELLY, JJ ;
KITCHEN, JG ;
DOUGHERTY, MJ ;
YIH, DF ;
MCGEEHIN, FC ;
SHUCK, JW ;
PHIAMBOLIS, TP .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :888-895
[2]   Phenotypic heterogeneity of the endothelium II. Representative vascular beds [J].
Aird, William C. .
CIRCULATION RESEARCH, 2007, 100 (02) :174-190
[3]   Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure [J].
Alaeddini, J ;
Uber, PA ;
Park, MH ;
Scott, RL ;
Ventura, HO ;
Mehra, MR .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (11) :1475-1477
[4]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[5]   Development of a ventilatory classification system in patients with heart failure [J].
Arena, Ross ;
Myers, Jonathan ;
Abella, Joshua ;
Peberdy, Mary Ann ;
Bensimhon, Daniel ;
Chase, Paul ;
Guazzi, Marco .
CIRCULATION, 2007, 115 (18) :2410-2417
[6]   Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension [J].
Argenziano, M ;
Choudhri, AF ;
Moazami, N ;
Rose, EA ;
Smith, CR ;
Levin, HR ;
Smerling, AJ ;
Oz, MC .
ANNALS OF THORACIC SURGERY, 1998, 65 (02) :340-344
[7]   Diastolic heart failure [J].
Maurer, MS ;
Packer, M ;
Burkhoff, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (11) :1143-1143
[8]   Effects of 5′-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure:: A double-blind, placebo-controlled clinical trial [J].
Behling, Alice ;
Rohde, Luis E. ;
Colombo, Fernanda C. ;
Goldraich, Livia A. ;
Stein, Ricardo ;
Clausell, Nadine .
JOURNAL OF CARDIAC FAILURE, 2008, 14 (03) :189-197
[9]   Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma [J].
Berg, JT ;
Breen, EC ;
Fu, ZX ;
Mathieu-Costello, O ;
West, JB .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (06) :1920-1928
[10]   Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy [J].
Bleeker, GB ;
Schalij, MJ ;
Nihoyannopoulos, P ;
Steendijk, P ;
Molhoek, SG ;
van Erven, L ;
Bootsma, M ;
Holman, ER ;
van der Wall, EE ;
Bax, JJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (12) :2264-2269